A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Trial Profile

A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Avelumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms JAVELIN Merkel 200
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 06 Mar 2018 Results (n=19) of analysis assessing impact of Merkel-cell-carcinoma and its management on patients' lives published in The Patient - Patient-Centered Outcomes Research
    • 22 Feb 2018 Results (n=1738) of pooled analysis of JAVELIN and JAVELIN Merkel 200 studies assessing safety, published in the Cancer.
    • 22 Feb 2018 According to an EMD Serono media release, based on the results of this trial (n=88), Health Canada has approved BAVENCIO (avelumab for injection) for the treatment of metastatic Merkel cell carcinoma (MCC) in previously treated adults, under accelerated approval framework.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top